In 2019, the company raised PLN 5.1 million under the “Fast Track” programme. These funds will be used to develop another biological medicine, this time for horses. Bioceltix won the Start-Up Challenge competition during the European Start-Up Days, an event accompanying the XI European Economic Congress in Katowice. Moreover, they were awarded in the category of medicine, health, medical technology and pharmacy. The jury appreciated the ambitious clinical research plan and scalable business model.
Our portfolio company also participates in Sebastian Kulczyk’s acceleration program – InCredibles. It was also a great honour to be included in the “25 best Polish startups” ranking of My company Polska magazine.
In 2020, thanks to financing from NCBR, Bioceltix will launch a new project worth almost PLN 7.2 million. Within its framework, they will develop, clinically test and produce the first, serial drug based on MSC, designed to treat arthritis in horses.
Congratulations on such a successful year 2019 and we keep our fingers crossed for further development in the coming year!
To find out more please visit the article: https://bit.ly/36GNE6Q.